Swedish Orphan Biovitrum company profile
Company profile
Swedish Orphan Biovitrum has 2,207 employees and is headquartered in Stockholm, Sweden.
Its medicines are sold across Europe, North America, the Middle East, Asia and Australia. The company works in three segments, Haematology, Immunology and Specialty Care, and its portfolio centres on treatments for haemophilia, such as Alprolix, ALTUVOCT and Elocta/Eloctate, alongside Synagis for respiratory syncytial virus in infants, Kineret for inflammatory conditions including rheumatoid arthritis, and Zynlonta for adult patients with lymphoma. It also markets Doptelet, Gamifant and Orfadin, and develops drug substances for Pfizer's ReFacto AF/Xyntha. Collaboration agreements are in place with Sanofi, Apellis Pharmaceuticals, ADC Therapeutics and Cartesian Therapeutics, and a strategic partnership with Innate Pharma supports the TELLOMAK-3 Phase 3 study in cutaneous T cell lymphoma.
In the fiscal year ended December 2025, the company reported revenue of SEK 28.2 billion, up 8.5% from the previous year, and a net profit of SEK 478 million. It had 2,207 employees. The company is headquartered in Stockholm, Sweden, and was incorporated in 1939.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Sweden
- Headquarters
- Norra Stationsgatan 93A, Stockholm
- Employees
- 2,207
- Chief executive
- Guido Oelkers
- Founded
- 1939
- Fiscal year
- January - December
- Listing
- SOBI · Nasdaq Stockholm
- Currency
- SEK
- ISIN
- SE0000872095
- Website
- sobi.com
Swedish Orphan Biovitrum and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Swedish Orphan BiovitrumSOBI | Sweden | $16.27B | 2,207 | 30.9% | 25.0 |
| IpsenIPN | France | $14.2B | 5,535 | 27.4% | 25.5 |
| H. LundbeckHLUN.A | Denmark | $8.49B | 5,000 | 24.4% | 14.2 |
| HaleonHLN | United Kingdom | $40.15B | 24,535 | 23.5% | 19.3 |
| Sandoz GroupSDZ | Switzerland | $43.57B | 20,000 | 9.3% | 72.3 |
| Galderma GroupGALD | Switzerland | $51.94B | 7,676 | 19.1% | 64.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
